Recently medicinal cannabis has been at the forefront of media attention in the...
Talzenna (talazoparib) for the Treatment of Advanced Breast Cancer
Talzenna™ (talazoparib) is an inhibitor of the poly adenosine diphosphate (ADP) ribose polymerase (PARP) enzyme that is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) negative breast cancer in adult patients with the BRCA-mutated (gBRCAm) gene.
Deals this week: OSE Immunotherapeutics, Tango Therapeutics, Provention Bio
OSE Immunotherapeutics has received global rights to autoimmune disease candidate FR104 from Janssen Biotech.
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
Deals this week: AgaMatrix, Kissei Pharmaceutical, 89Bio
Arcadia Group is to use AgaMatrix's blood glucose monitoring (BGM) technology for diabetes products marketed under the Choice brand according to a partnership signed between the companies.
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
TIBSOVO (ivosidenib) for Relapsed or Refractory AML
TIBSOVO® (ivosidenib) is a small molecule inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML) with isocitrate dehydrogenase-1 (IDH1) mutation.
Deals this week: Kazia Therapeutics, Zymeworks, CANbridge
Kazia Therapeutics has signed a collaboration agreement with Dana-Farber Cancer Institute to trial GDC-0084 for the treatment of patients diagnosed with breast cancer that has spread to the brain.
M&As this week: NeoGenomics, Two Labs, Purdue Pharma
NeoGenomics has signed an agreement to acquire Genoptix for a cash consideration of $125m in addition to one million NeoGenomics common stock shares
Fleet Bioprocessing to Attend Gyrolab Seminar
Fleet Bioprocessing has announced it will be attending the Gyrolab seminar 'Automating PK/PD, Immunogenicity and Affinity Measurement' at Babraham Research Campus in Cambridge.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.